Drug maker agrees to stop selling Opana ER because of misuse

July 6, 2017 Julie Miller

Julie Miller, Editor in Chief

Endo Pharmaceuticals on Thursday agreed to remove its long-acting Opana ER pain drug from the market, about a month after FDA requested that the company stop selling the product because of the growing incidents of misuse.

Previous Article
Timberline Knolls names new CEO

Julie Miller, Editor in ChiefA longtime clinician at Timberline Knolls in Illinois, Colleen Kula, LCPC, has...

Next Article
Messaging often fails to meet HIPAA requirements

David RathsProviders like the convenience of messaging colleagues and patients, not realizing that they cou...

×

Have Behavioral Health Business updates sent to your inbox today!

First Name
Last Name
Thank you!
Error - something went wrong!